Repurposing Nucleoside Analogs for Human Coronaviruses
Keivan Zandi, Franck Amblard, Katie Musall, Jessica Downs-Bowen, Ruby Kleinbard, Adrian Oo, Dongdong Cao, Bo Liang, Olivia Ollinger Russell, Tamara R. McBrayer, Leda Bassit, Baek Kim, Raymond F. Schinazi
Abstract
Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. Of significance, sofosbuvir demonstrated no antiviral effect against CoV-2, and its triphosphate did not inhibit CoV-2 RNA polymerase.
Topics & Concepts
NucleosideCoronavirusVirologyNucleoside analogueRepurposingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Nucleoside triphosphateBetacoronavirusMedicineCoronaviridaeCoronavirus disease 2019 (COVID-19)BiologyPharmacologyNucleotideDiseaseGeneBiochemistryInfectious disease (medical specialty)Internal medicineEcologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studiesinterferon and immune responses